Ocular Therapeutix Inc OCUL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:02 PM EDT
4.34UNCH (UNCH)
Volume
13,259
Close
4.34quote price arrow up+0.25 (+6.11%)
Volume
524,267
52 week range
2.91 - 13.75
Loading...
  • Open4.03
  • Day High4.39
  • Day Low4.01
  • Prev Close4.09
  • 52 Week High13.75
  • 52 Week High Date07/06/21
  • 52 Week Low2.91
  • 52 Week Low Date05/27/22

Key Stats

  • Market Cap333.14M
  • Shares Out76.76M
  • 10 Day Average Volume0.59M
  • Dividend-
  • Dividend Yield-
  • Beta1.52
  • YTD % Change-37.73

KEY STATS

  • Open4.03
  • Day High4.39
  • Day Low4.01
  • Prev Close4.09
  • 52 Week High13.75
  • 52 Week High Date07/06/21
  • 52 Week Low2.91
  • 52 Week Low Date05/27/22
  • Market Cap333.14M
  • Shares Out76.76M
  • 10 Day Average Volume0.59M
  • Dividend-
  • Dividend Yield-
  • Beta1.52
  • YTD % Change-37.73

RATIOS/PROFITABILITY

  • EPS (TTM)-0.29
  • P/E (TTM)-14.78
  • Fwd P/E (NTM)-5.22
  • EBITDA (TTM)-73.31M
  • ROE (TTM)-27.22%
  • Revenue (TTM)49.37M
  • Gross Margin (TTM)90.25%
  • Net Margin (TTM)-45.00%
  • Debt To Equity (MRQ)65.24%

EVENTS

  • Earnings Date08/08/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ocular Therapeutix Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocularitching associated with allergic conjunctivitis. Its earlier stage development assets include axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for...
Charles Warden
Independent Chairman of the Board
Antony Mattessich
President, Chief Executive Officer, Director
Donald Notman Jr.
Chief Financial Officer
Philip Strassburger Esq., J.D.
General Counsel
Address
SUITE 101, 36 CROSBY DRIVE
Bedford, MA
01730
United States

Top Peers

SYMBOLLASTCHG%CHG
EYPT
EyePoint Pharmaceuticals Inc
7.76+0.01+0.13%
OPTN
OptiNose Inc
3.81+0.17+4.67%
OMER
Omeros Corp
3.09-1.55-33.41%
ESPR
Esperion Therapeutics Inc
6.99+0.54+8.37%
HROW
Harrow Health Inc
7.03-0.11-1.54%